Free Beta: Procurement discovery is free; verify every opportunity on SAM.gov. Source status
OtherClosed

Emergent Drug Panel-Version 2 (EDP-V2) Kit

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › CENTERS FOR DISEASE CONTROL AND PREVENTION › CDC OFFICE OF ACQUISITION SERVICES

Response deadlineSep 14, 2026 11:00 AM EDT
View official notice on SAM.gov (opens in a new tab)
Verify before acting. Users must verify deadlines, amendments, attachments, eligibility, and submission requirements on the official SAM.gov notice. Read the Data Disclaimer.

Key decision factors

Response deadline
Sep 14, 2026 11:00 AM EDT
Posted
Sep 9, 2026 12:00 AM EDT
Notice type
Presolicitation
Set-aside
Not provided or not applicable
PSC
6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
Place of performance
Atlanta, Georgia
Current status
Closed

Notice details

Official status
Closed
Normalized group
Other
Notice ID
24aa2d1a239f4cd7b9a767eccea783b5
Solicitation number
000HCNBG-2026-99823

Description

Displayed as sanitized plain text from SAM.gov. Retrieved Sep 10, 2026 10:24 PM EDT.

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Cayman Chemical Company, Inc. for the design, manufacture, distribution, and associated laboratory support services for the Emergent Drug Panel-Version 2 (EDP-V2) Kit, a new product line addition within CDC's Traceable Opioid Material (TOM®) Kit program, and continued distribution, product support, and data collection services for existing Emergent Drug Panel (EDP) Kit products. The anticipated period of performance is 09/30/2026 through 09/29/2027. The requirement will include four option years for design and manufacture of additional kits as well as continuous distribution. The Government intends to solicit and negotiate with only one source under the authority of FAR 12.102(a). CDC requires a contractor to: 1. Design and manufacture EDP-V2 kits containing reference materials for emerging synthetic opioids and related drugs of concern (including synthetic opioids, novel benzodiazepines, synthetic cathinones, and related novel psychoactive substances) contributing to the opioid epidemic, meeting or exceeding Current Good Manufacturing Practice (cGMP) standards; 2. Obtain and maintain a DEA exemption/registration status enabling distribution of controlled and non-controlled reference materials to CDC-approved laboratories; 3. Distribute EDP-V2 kits and all other existing EDP Kit product lines to approved laboratories nationally; 4. Provide ongoing product support, customer service, and technical assistance to recipient laboratories for all EDP Kit products; 5. Collect, maintain, and report kit distribution and use-case metrics to CDC in accordance with OMB-approved data collection requirements; and 6. Conduct stability testing on existing EDP Kit materials nearing expiration to determine potential for shelf-life extension. This notice of intent is not a request for competitive quotations; however, all quotations/responses received prior to the date and time below will be considered by the government. NOTE: Interested vendors must clearly provide evidence of their capability to be considered. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the Contracting Officer at xur0@cdc.gov by 11:00AM (ET) on 09/14/2026.

Attachments

No attachments were reported for this notice. MaroNest reflects only what the source data reports — review the official SAM.gov notice (opens in a new tab) to confirm whether related documents or amendments exist.

Contacts

Taylor Wellman
Primary
xur0@cdc.gov

Personalized relevance

Would this fit your company?

Create company profile information with a free account to see a deterministic, explainable relevance score. Matching does not determine eligibility or win probability.

Create Free Account

Pursuit risk (separate from your match score)

Strong pursuit warning

This notice contains language indicating a sole-source or otherwise restricted procurement. Review the cited evidence before investing time in a response.

Detected in

  • Description“The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Cayman Chemical Company, Inc. for the design, manufacture, distribution, and associated laboratory support servic”

Pursuit risk is evaluated separately from your match score above and never changes it. This is not a legal or eligibility determination — verify against the official SAM.gov notice and attachments.